Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF) Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble talked with Share Talk’s Zak Mir about the company’s conference season.
European Green Transition (AIM: EGT) Option Agreement to Sell Pajala Copper Project
European Green Transition (AIM: EGT), a company seeking to acquire and transform revenue stage businesses supporting the green energy transition in Europe, announces that it has entered into an exclusive
European Green Transition (AIM: EGT) Appointment of Independent Non-Executive Director
European Green Transition (AIM: EGT), a company seeking to acquire and transform revenue stage businesses supporting the green energy transition in Europe, announces the appointment of Mick Kearney as an
Poolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025
Well-funded with multiple upcoming clinical milestones
European Green Transition: From Exploration to Execution at The Investor Summit
A Company in Transition
Poolbeg Pharma (AIM: POLB) POLB 001 Phase 2a Trial Update
ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK
European Green Transition (AIM: EGT) Interim results and M&A strategy update
European Green Transition (AIM: EGT), a company which aims to capitalise on the opportunities created by the green energy transition in Europe, announces its unaudited results for the six months
European Green Transition: From Exploration to Execution at The Investor Summit
A Company in Transition
Poolbeg Pharma: New Capital, New Catalysts as POLB 001 Advances in the Clinic
Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.865 million equity raise and a series of high-impact developments across
Poolbeg Pharma: New Capital, New Catalysts as POLB 001 Advances Toward the Clinic
Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.7 million equity raise and a series of high-impact developments across
European Green Transition: From Exploration to Execution as Cathal Friel Takes the Helm
European Green Transition plc (AIM: EGT) recently released its audited results for the year ended 31 December 2024, marking a pivotal period of transformation for the green economy investment company.
Poolbeg Pharma PLC (AIM:POLB) Director/PDMR Shareholding
Director Dealing